• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for TYMLOS issued to RADIUS HEALTH INC

    12/23/21 5:39:20 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary
    Get the next $RDUS alert in real time by email
    New Drug Application (NDA): 208743
    Company: RADIUS HEALTH INC
    • Email
    • Medication Guide
    • Summary Review

    Products on NDA 208743

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    TYMLOS ABALOPARATIDE 3.12MG/1.56ML (2MG/ML) SOLUTION;SUBCUTANEOUS Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 208743

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    04/28/2017 ORIG-1 Approval Type 1 - New Molecular Entity and Type 4 - New Combination STANDARD Label (PDF)
    Letter (PDF)
    Review
    Summary Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208743Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000SumR.pdf
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    12/22/2021 SUPPL-10 Efficacy-Labeling Change With Clinical Data

    Label is not available on this site.

    09/20/2021 SUPPL-9 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208743s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208743Orig1s009ltr.pdf
    10/23/2020 SUPPL-7 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208743s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208743Orig1s007ltr.pdf
    06/20/2018 SUPPL-4 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s004ltr.pdf
    10/17/2018 SUPPL-3 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s003ltr.pdf
    02/05/2018 SUPPL-1 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s001ltr.pdf

    Labels for NDA 208743

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    09/20/2021 SUPPL-9 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208743s009lbl.pdf
    10/23/2020 SUPPL-7 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208743s007lbl.pdf
    10/17/2018 SUPPL-3 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s003lbl.pdf
    06/20/2018 SUPPL-4 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s004lbl.pdf
    02/05/2018 SUPPL-1 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s001lbl.pdf
    04/28/2017 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf
    Get the next $RDUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDUS

    DatePrice TargetRatingAnalyst
    12/2/2024$22.00Neutral
    Goldman
    5/30/2024Sell → Neutral
    Seaport Research Partners
    2/28/2024$17.50Neutral → Sell
    Seaport Research Partners
    12/14/2023Neutral
    Seaport Research Partners
    6/8/2022$8.00Underperform → Neutral
    BofA Securities
    5/23/2022$7.00Mkt Perform
    SVB Leerink
    12/10/2021$18.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    12/10/2021$33.00 → $12.00Buy → Neutral
    Goldman Sachs
    More analyst ratings

    $RDUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Radius Recycling with a new price target

    Goldman initiated coverage of Radius Recycling with a rating of Neutral and set a new price target of $22.00

    12/2/24 8:18:29 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Radius Recycling upgraded by Seaport Research Partners

    Seaport Research Partners upgraded Radius Recycling from Sell to Neutral

    5/30/24 8:09:18 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Radius Recycling downgraded by Seaport Research Partners with a new price target

    Seaport Research Partners downgraded Radius Recycling from Neutral to Sell and set a new price target of $17.50

    2/28/24 6:52:19 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    $RDUS
    SEC Filings

    View All

    SEC Form 15-12G filed by Radius Recycling Inc.

    15-12G - RADIUS RECYCLING, INC. (0000912603) (Filer)

    7/21/25 10:14:11 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Radius Recycling Inc.

    SCHEDULE 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)

    7/15/25 4:03:17 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    SEC Form S-8 POS filed by Radius Recycling Inc.

    S-8 POS - RADIUS RECYCLING, INC. (0000912603) (Filer)

    7/10/25 4:30:29 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    $RDUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TYMLOS issued to RADIUS HEALTH INC

    Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-13) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/19/2022. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy

    12/21/22 4:37:57 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    FDA Approval for TYMLOS issued to RADIUS HEALTH INC

    Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/22/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy

    12/23/21 5:39:20 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    FDA Tentative Approval for TYMLOS issued to RADIUS HEALTH INC

    Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Tentative Approval' on 10/28/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy

    10/29/21 4:44:50 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    $RDUS
    Leadership Updates

    Live Leadership Updates

    View All

    Radius Recycling, Inc. Appoints Marc Hathhorn as Chief Operating Officer

    PORTLAND, Ore., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today announced the appointment of Marc Hathhorn as Executive Vice President and Chief Operating Officer, effective November 1, 2024. Hathhorn joins Radius from Peabody Energy Corporation (NYSE:BTU) and brings more than 30 years of leadership experience in the mining industry. Most recently, Hathhorn held the position of President--Global Operations at Peabody Energy Corporation (NYSE:BTU), overseeing 5,000 employees and 17 coal mines across the U.S. and Australia. Under Hathhorn's leadership, Peabody achieved multiple safety performance awards, exceeded environmental management and compliance goals, an

    11/8/24 4:30:00 PM ET
    $BTU
    $RDUS
    Coal Mining
    Energy
    Industrial Specialties
    Consumer Discretionary

    Radius Recycling, Inc. Appoints Mauro Gregorio to its Board of Directors

    PORTLAND, Ore., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) announced that its Board of Directors has appointed Mauro Gregorio, the recently retired President of the Performance Materials & Coatings Division at Dow Inc. (NYSE:DOW), as a new independent director, effective November 1, 2024. Mr. Gregorio will serve on the Audit Committee and the Compensation and Human Resources Committee of the Board. Over his nearly 40-year career at Dow, Mr. Gregorio served in multiple roles, including leading the post-acquisition integration of Dow Corning, overseeing the company's feedstock and energy business unit, and serving as global Vice President for the Hygiene and Medi

    10/24/24 4:00:00 PM ET
    $DOW
    $EXP
    $RDUS
    Major Chemicals
    Industrials
    Building Materials
    Industrial Specialties

    Radius Files Definitive Proxy and Mails Letter to Stockholders

    Urges Stockholders to Vote "FOR" Radius' Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card Details Company's Significant Progress Since 2020, Under Refreshed Board and Management Team BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS) today announced that it has filed its definitive proxy statement with the Securities and Exchange Commission ("SEC") for its upcoming Annual Meeting of Stockholders, which will be held online on July 8, 2022. Stockholders of record as of June 3, 2022, will be entitled to vote at the meeting. In c

    6/6/22 7:30:00 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    $RDUS
    Financials

    Live finance-specific insights

    View All

    Radius Recycling Reports Third Quarter Fiscal 2025 Financial Results

    Significant Improvements Sequentially and Year-Over-Year Higher Ferrous, Nonferrous and Finished Steel Sales Volumes Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 01, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) ("Radius" or the "Company") today reported results for the third quarter of fiscal 2025 ended May 31, 2025. The Company reported a loss per share from continuing operations of $(0.59) and a net loss of $(16) million in the third quarter of fiscal 2025, a significant improvement compared to ($1.15) and ($33) million, respectively, in the second quarter of fiscal 2025. Adjusted

    7/1/25 8:00:00 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Radius Recycling Reports Second Quarter Fiscal 2025 Financial Results

    Ferrous and Finished Steel Sales Volumes Up Year-Over-Year Positive Operating and Free Cash Flow Radius Board Declares Quarterly Dividend PORTLAND, Ore., April 04, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) ("Radius" or the "Company") today reported results for the second quarter of fiscal 2025 ended February 28, 2025. The Company reported a loss per share from continuing operations of $(1.15) and a net loss of $(33) million in the second quarter of fiscal 2025, compared to ($1.19) and ($34) million, respectively, in the prior year second quarter. Adjusted EBITDA was approximately break-even in the second quarter of fiscal 2025, compared to $3 million in the prior ye

    4/4/25 8:30:00 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Radius Recycling Reports First Quarter Fiscal 2025 Financial Results

    PORTLAND, Ore., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today reported results for the first quarter of fiscal 2025 ended November 30, 2024. The Company reported a loss per share from continuing operations of $(1.30) and a net loss of $(37) million in the first quarter of fiscal 2025, compared to ($0.64) and ($18) million, respectively, in the prior year first quarter, with the difference substantially driven by a detriment on income tax in the current quarter. Adjusted EBITDA was break-even in the first quarter of fiscal 2025, compared to $1 million in the prior year first quarter. Adjusted loss per share from continuing operations was $(1.33) in the firs

    1/7/25 4:30:00 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    $RDUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Radius Recycling Reports Third Quarter Fiscal 2025 Financial Results

    Significant Improvements Sequentially and Year-Over-Year Higher Ferrous, Nonferrous and Finished Steel Sales Volumes Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 01, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) ("Radius" or the "Company") today reported results for the third quarter of fiscal 2025 ended May 31, 2025. The Company reported a loss per share from continuing operations of $(0.59) and a net loss of $(16) million in the third quarter of fiscal 2025, a significant improvement compared to ($1.15) and ($33) million, respectively, in the second quarter of fiscal 2025. Adjusted

    7/1/25 8:00:00 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Radius Recycling Reports Second Quarter Fiscal 2025 Financial Results

    Ferrous and Finished Steel Sales Volumes Up Year-Over-Year Positive Operating and Free Cash Flow Radius Board Declares Quarterly Dividend PORTLAND, Ore., April 04, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) ("Radius" or the "Company") today reported results for the second quarter of fiscal 2025 ended February 28, 2025. The Company reported a loss per share from continuing operations of $(1.15) and a net loss of $(33) million in the second quarter of fiscal 2025, compared to ($1.19) and ($34) million, respectively, in the prior year second quarter. Adjusted EBITDA was approximately break-even in the second quarter of fiscal 2025, compared to $3 million in the prior ye

    4/4/25 8:30:00 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    RADIUS RECYCLING to be Acquired by U.S. Subsidiary of TOYOTA TSUSHO CORPORATION (TTC), Accelerating Investment in Future Growth

    Radius Recycling Shareholders to Receive $30.00 in Cash Per Share, Delivering Significant Value TTC's Investments to Accelerate Radius Recycling's Growth Strategies and Strengthen Resiliency TTC Committed to Honoring Collective Bargaining Agreements and Compensation and Benefits Programs for All Radius Recycling Employees PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) ("Radius" or the "Company") today announced that it has entered into a definitive merger agreement with Toyota Tsusho America, Inc. ("TAI"), a U.S. subsidiary of Toyota Tsusho Corporation (8015.T) ("TTC"), under which TAI will acquire all shares of Radius for $30.00 per share

    3/13/25 5:00:00 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    $RDUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hunter Rhonda D returned $1,357,619 worth of shares to the company (45,254 units at $30.00), closing all direct ownership in the company (SEC Form 4)

    4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)

    7/10/25 4:54:15 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Chairman, President & CEO Lundgren Tamara L. returned $38,365,800 worth of shares to the company (1,278,860 units at $30.00), closing all direct ownership in the company (SEC Form 4)

    4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)

    7/10/25 4:52:19 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    SVP, CFO Gaggini Stefano R. returned $2,708,430 worth of shares to the company (90,281 units at $30.00), closing all direct ownership in the company (SEC Form 4)

    4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)

    7/10/25 4:51:41 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    $RDUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Radius Recycling Inc.

    SC 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)

    11/14/24 12:27:50 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Radius Recycling Inc.

    SC 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)

    11/12/24 4:45:51 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Radius Recycling Inc.

    SC 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)

    11/4/24 1:18:16 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary